Male patients with non-small cell lung cancer (NSCLC) have a 24% reduction in the risk of disease progression (A). Male patients with non-small cell lung cancer (NSCLC) have a 24% reduction in the risk of disease progression (A). Women have a decreased benefit from anti-PD1 inhibitors nivolumab and pembrolizumab (B). Funnel plots showing publication bias in meta-analysis of male (C) or female patients (D). Joseph A Pinto et al. ESMO Open 2018;3:e000344 Copyright © European Society for Medical Oncology. All rights reserved.